CPE and Alzheimer disease: 3xTg-AD and non-Tg mice received bilateral hippocampal injections of either AAV-GFP, NF-α1/CPE, or NF-α1/CPE-E342Q at age 2 months (presymptomatic) and they then underwent a series of behavioral tests at age 9 months when cognitive decline was evident (Fig 1A).